Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma

Abstract

To test the hypothesis that maximal androgen blockade improves the effectiveness of the treatment of prostatic cancer, we conducted a randomized, double-blind trial in patients with disseminated, previously untreated prostate cancer (stage D2). All 603 men received leuprolide, an analogue of gonadotropin-releasing hormone that inhibits the release of gonadotropins, in combination with either placebo or flutamide, a nonsteroidal antiandrogen that inhibits the binding of androgens to the cell nucleus. As compared with the 300 patients receiving leuprolide and placebo, the 303 patients randomly assigned to receive leuprolide and flutamide had a longer progression-free survival (16.5 vs. 13.9 months; P = 0.039) and an increase in the median length of survival (35.6 vs. 28.3 months; P = 0.035). The differences between the treatments were particularly evident for men with minimal disease and good performance status; however, further studies should be conducted in this subgroup. Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade, when leuprolide alone often produces a painful flare in the disease. We conclude that in patients with advanced prostate cancer, treatment with leuprolide and flutamide is superior to treatment with leuprolide alone.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm198908173210702

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 9

  1. Huggins, 1941, Cancer Res, 1, 293
  2. Sufrin, 1976, Invest Ural, 13, 429
  3. Coffey, 1981, Urology, 17, 17
  4. Wake, 1982, Cancer Res, 42, 4131
  5. Isaacs, 1982, Cancer Res, 42, 2353
  6. Brendler, 1962, Cancer Chemother Rep, 16, 323
  7. Isaacs, 1981, Cancer Res, 41, 5070
  8. Ellis, 1985, Cancer Res, 45, 6041
  9. Geller J, Albert JD. Antiandrogens and small doses of estrogen therapy as the preferred treatment for prostatic cancer. In: Hormones and cancer. New York: Raven Press, 1984.

Cited by

See all 1,464

Metadata

Authors
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J.
Affiliations
  • University of Colorado Denver (US)
  • National Cancer Institute (US)
  • Fred Hutch Cancer Center (US)
Venue
New England Journal of Medicine
Published
1989-08-17
Volume
321
Issue
7
Pages
419-424
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2014145760
Cited by
1,464
References
29
Citations by year
2026: 5 · 2025: 6 · 2024: 11 · 2023: 18 · 2022: 11 · 2021: 17 · 2020: 19 · 2019: 25 · 2018: 20 · 2017: 25 · 2016: 30 · 2015: 43 · 2014: 49 · 2013: 50 · 2012: 43
FWCI
62.74
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
leuprolide, flutamide, androgen deprivation therapy, combined androgen blockade, prostate cancer, advanced prostate cancer, progression-free survival, survival, GnRH analogues, nonsteroidal antiandrogens
MeSH terms
Aged, Aged, 80 and over, Anilides, Antineoplastic Agents, Clinical Trials as Topic, Double-Blind Method, Drug Therapy, Combination, Flutamide, Humans, Gonadotropin-Releasing Hormone, Male, Middle Aged, Prostatic Neoplasms, Random Allocation, Leuprolide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma. https://app.cochat.ai/papers/10.1056/nejm198908173210702
The paper
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989). A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejm198908173210702

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.